M Schambelan
Overview
Explore the profile of M Schambelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
1885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lo J, Mulligan K, Noor M, Schwarz J, Halvorsen R, Grunfeld C, et al.
J Clin Endocrinol Metab
. 2001 Aug;
86(8):3480-7.
PMID: 11502767
GH has been proposed as a therapy for patients with HIV-associated fat accumulation, but the pharmacological doses (6 mg/d) used have been associated with impaired fasting glucose and hyperglycemia. In...
2.
Noor M, Lo J, Mulligan K, Schwarz J, Halvorsen R, Schambelan M, et al.
AIDS
. 2001 Jun;
15(7):F11-8.
PMID: 11399973
Background: Therapy with HIV protease inhibitors (PI) has been associated with hyperglycemia, hyperlipidemia and changes in body composition. It is unclear whether these adverse effects are drug related, involve an...
3.
Lo J, Schambelan M
J Clin Endocrinol Metab
. 2001 Jun;
86(6):2338-43.
PMID: 11397819
No abstract available.
4.
Mulligan K, Tai V, Algren H, Abrams D, Leiser R, Lo J, et al.
J Acquir Immune Defic Syndr
. 2001 Jun;
26(5):443-8.
PMID: 11391163
To determine whether HIV infection, the wasting syndrome, or nucleoside analog reverse transcriptase inhibitor (NRTI) or protease inhibitor (PI) therapy uniquely affect fat distribution in men, we performed manual regional...
5.
Kaplan G, Thomas S, Fierer D, Mulligan K, Haslett P, FESSEL W, et al.
AIDS Res Hum Retroviruses
. 2000 Oct;
16(14):1345-55.
PMID: 11018854
A double-blind, placebo-controlled trial of efficacy and safety of thalidomide in AIDS-associated wasting was carried out. Ninety-nine of 103 male patients had at least one on-study measurement (intent-to-treat [ITT] cohort)....
6.
Giacchetti G, Sechi L, Griffin C, Don B, Mantero F, Schambelan M
J Hypertens
. 2000 Jun;
18(6):695-702.
PMID: 10872553
Objective: Fructose feeding induces hypertension, insulin-resistance and hypertriglyceridemia in Sprague-Dawley rats. The mechanisms of fructose-induced hypertension are as yet unknown. Here we investigate the effects of fructose feeding and of...
7.
Mulligan K, Grunfeld C, Tai V, Algren H, Pang M, Chernoff D, et al.
J Acquir Immune Defic Syndr
. 2000 Mar;
23(1):35-43.
PMID: 10708054
Although protease inhibitor (PI) therapy has improved the clinical status of patients with HIV infection, concerns have arisen that such treatment may have deleterious effects on glucose control, lipid metabolism,...
8.
Khovidhunkit W, Memon R, Shigenaga J, Pang M, Schambelan M, Mulligan K, et al.
Metabolism
. 1999 Dec;
48(12):1524-31.
PMID: 10599983
Platelet-activating factor (PAF) acetylhydrolase (PAF-AH) catalyzes the hydrolysis of PAF, a mediator of inflammation, as well as other biologically active oxidized phospholipids. In humans, plasma PAF-AH activity is bound to...
9.
Mulligan K, Tai V, Schambelan M
JPEN J Parenter Enteral Nutr
. 1999 Nov;
23(6 Suppl):S202-9.
PMID: 10571456
Body wasting and loss of lean body mass (LBM) have been associated with increased mortality and disease progression, and reduced quality of life, in patients with human immunodeficiency virus (HIV)...
10.
Johansen K, Mulligan K, Schambelan M
JAMA
. 1999 Apr;
281(14):1275-81.
PMID: 10208142
Context: Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and...